Fresh off making its U.S. landfall, British CRO TranScrip Partners has expanded into Hong Kong, bringing its development and marketing services to Asia.
With the launch of its Hong Kong office, TranScrip has an up-front seat for the burgeoning drug development scene in the Asia-Pacific region, the company said.
"Establishing TranScrip's office in Hong Kong is the next step in our global strategy for growth and will consolidate our presence in Asia-Pacific, a region which we see as being highly significant with regard to pharmaceutical drug development and sales," Managing Partner Flic Gabbay said in a statement.
The ribbon-cutting follows TranScrip's April expansion into the U.S., when the CRO set up shop in Philadelphia. TranScrip launched an operation in Australia late last year.
The CRO bills itself as an end-to-end solutions for clients, handling drug development, medical affairs, pharmacovigilance, regulatory services and medical writing for pre- and post-approval. The company has thus far partnered with more than 80 companies across four continents.
- read the announcement